Claim being checked · Version 1 · Reviewed
“Thymosin alpha-1 reduced 28-day deaths in the large TESTS sepsis trial.”
Written and source-checked by Anthony Treviso, founder of The Peptide Field.
No dosing advice. This guide explains research. It was not independently medically reviewed, and it does not diagnose, prescribe, or recommend treatment.
Misleading. This statement leaves out a limit that changes its meaning.
Answer scope
This verdict checks the exact claim in the heading. It is not a universal grade for Thymosin alpha-1.
01 · Answer
Misleading
The corrected result was 23.4% with thymosin alpha-1 and 24.1% with placebo. The study found no clear difference in 28-day deaths.
- What kind of evidence this is
- Randomized human outcomes. This answer uses a study that assigned people to groups by chance and measured a health outcome.
- What this answer covers
- The TESTS study randomized 1,106 adults with sepsis at 22 centers in China. The corrected analysis applies only to this study and outcome. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
- Question type
- Clinical outcomes. What a study measured about people's health, symptoms, or ability to function.
02 · Sources
Read the sources behind this answer
01Large randomized TESTS sepsis trialThe BMJ · Randomized trial · 2025
Supports the corrective verdict02Correction to the TESTS sepsis trialThe BMJ · Reference · 2025
Supports the corrective verdict
Supports the corrective verdict02Correction to the TESTS sepsis trialThe BMJ · Reference · 2025
Supports the corrective verdict
- Editorial review
- Internal editorial review recorded
- Source review
- Anthony Treviso · Founder and responsible editor
- Medical review status
- Not independently medically reviewed. Editorial source review does not replace medical review.